Search
ell
eng
ell
eng
Menu
Home
About Us
History
Products
Careers
News
Contact Us
Home
News
Home
News
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in
Read more
The Dates of the XXVII Edition of the International Fair Play Menarini Awards
Read more
O Γρηγόρης Πολίτης νέος Διευθύνων Σύμβουλος της Μenarini Hellas
Read more
Menarini Hellas 1989-2023 Γεώργιος Συκιανάκης: «Ολοκλήρωση μιας επιτυχημένης συνεργασίας»
Read more
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Read more
1
2
3
4
5